within Pharmacolibrary.Drugs.ATC.M;

model M01AX21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 4.6666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0010333333333333334,
    Tlag           = 4200
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AX21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diacerein is an anthraquinone derivative with anti-inflammatory and anti-osteoarthritic properties. It is primarily used in the treatment of osteoarthritis, especially in Europe and some other countries. Diacerein acts through inhibition of interleukin-1 and has been used as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs). Its use is approved in some regions but is limited or withdrawn in others due to gastrointestinal side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Nicolas, P, et al., &amp; Petitjean, O (1998). Clinical pharmacokinetics of diacerein. <i>Clinical pharmacokinetics</i> 35(5) 347–359. DOI:<a href=\"https://doi.org/10.2165/00003088-199835050-00002\">10.2165/00003088-199835050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9839088/\">https://pubmed.ncbi.nlm.nih.gov/9839088</a></p></li><li><p>Spencer, CM, &amp; Wilde, MI (1997). Diacerein. <i>Drugs</i> 53(1) 98–108. DOI:<a href=\"https://doi.org/10.2165/00003495-199753010-00007\">10.2165/00003495-199753010-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9010651/\">https://pubmed.ncbi.nlm.nih.gov/9010651</a></p></li><li><p>Debord, P, et al., &amp; Petitjean, O (1993). Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. <i>Fundamental &amp; clinical pharmacology</i> 7(8) 435–441. DOI:<a href=\"https://doi.org/10.1111/j.1472-8206.1993.tb01039.x\">10.1111/j.1472-8206.1993.tb01039.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8294081/\">https://pubmed.ncbi.nlm.nih.gov/8294081</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AX21;
